REFERENCES
- Greenlee R T, Murray T, Bolden S, Wingo P A. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7–33, [PUBMED], [INFOTRIEVE], [CSA]
- Nicholson S A, Beasley M B, Brambilla E, Hasleton P S, Colby T V, Sheppard M N, Falk R, Travis W D. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002; 26: 1184–1197, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sekido Y, Fong K M, Minna J D. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta 1998; 1378: F21–59, [PUBMED], [INFOTRIEVE], [CSA]
- Parkin D M, Pisani P, Lopez A D, Masuyer E. At least one in seven cases of cancer is caused by smoking. Global estimates for 1985. Int J Cancer 1994; 59: 494–504, [PUBMED], [INFOTRIEVE], [CSA]
- Mulshine J L, Day R W. Screening for lung cancer. N Engl J Med 2001; 344: 935–936, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mangelsdorf D J, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans R M. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835–839, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gearing K L, Gottlicher M, Teboul M, Widmark E, Gustafsson J A. Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci USA 1993; 90: 1440–1444, [PUBMED], [INFOTRIEVE], [CSA]
- Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999; 354: 141–148, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tontonoz P, Hu E, Spiegelman B M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994; 79: 1147–1156, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lambe K G, Tugwood J D. A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biochem 1996; 239: 1–7, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mueller E, Sarraf P, Tontonoz P, Evans R M, Martin K J, Zhang M, Fletcher C, Singer S, Spiegelman B M. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998; 1: 465–470, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sarraf P, Mueller E, Jones D, King F J, De Angelo D J, Partridge J B, Holden S A, Chen L B, Singer S, Fletcher C, Spiegelman B M. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4: 1046–1052, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Keshamouni V G, Reddy R C, Arenberg D A, Joel B, Thannickal V J, Kalemkerian G P, Standiford T J. Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 2004; 23: 100–108, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Satoh T, Toyoda M, Hoshino H, Monden T, Yamada M, Shimizu H, Miyamoto K, Mori M. Activation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cells. Oncogene 2002; 21: 2171–2180, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lee T W, Chen G G, Xu H, Yip J H, Chak E C, Mok T S, Yim A P. Differential expression of inducible nitric oxide synthase and peroxisome proliferator-activated receptor gamma in non-small cell lung carcinoma. European Journal of Cancer 2003; 39: 1296–1301, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992; 68: 879–887, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chen F, Law S W, O'Malley B W. Identification of two mPPAR related receptors and evidence for the existence of five subfamily members. Biochem Biophys Res Commun 1993; 196: 671–677, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645–650, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649–688, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig A J, Flier J S. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. J Biol Chem 1997; 272: 20230–20235, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kliewer S A, Umesono K, Noonan D J, Heyman R A, Evans R M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992; 358: 771–774, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Berger J, Moller D E. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409–435, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fajas L, Fruchart J C, Auwerx J. PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett 1998; 438: 55–60, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996; 137: 354–366, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nagy L, Tontonoz P, Alvarez J G, Chen H, Evans R M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93: 229–240, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Huang J T, Welch J S, Ricote M, Binder C J, Willson T M, Kelly C, Witztum J L, Funk C D, Conrad D, Glass C K. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999; 400: 378–382, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Willson T M, Cobb J E, Cowan D J, Wiethe R W, Correa I D, Prakash S R, Beck K D, Moore L B, Kliewer S A, Lehmann J M. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996; 39: 665–668, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Shibata T, Matsui K, Nagao K, Shinkai H, Yonemori F, Wakitani K. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol 1999; 364: 211–219, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Suh N, Wang Y, Williams C R, Risingsong R, Gilmer T, Willson T M, Sporn M B. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999; 59: 5671–5673, [PUBMED], [INFOTRIEVE], [CSA]
- Hwang B Y, Lee J H, Nam J B, Kim H S, Hong Y S, Lee J J. Two new furanoditerpenes from Saururus chinenesis and their effects on the activation of peroxisome proliferator-activated receptor gamma. J Nat Prod 2002; 65: 616–617, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Liang Y C, Tsai S H, Tsai D C, Lin-Shiau S Y, Lin J K. Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of peroxisome proliferator-activated receptor-gamma by flavonoids in mouse macrophages. FEBS Lett 2001; 496: 12–18, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kuroda M, Mimaki Y, Sashida Y, Mae T, Kishida H, Nishiyama T, Tsukagawa M, Konishi E, Takahashi K, Kawada T, Nakagawa K, Kitahara M. Phenolics with PPAR-gamma ligand-binding activity obtained from licorice (Glycyrrhiza uralensis roots) and ameliorative effects of glycyrin on genetically diabetic KK-A(y) mice. Bioorg Med Chem Lett 2003; 13: 4267–4272, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wang Y, Porter W W, Suh N, Honda T, Gribble G W, Leesnitzer L M, Plunket K D, Mangelsdorf D J, Blanchard S G, Willson T M, Sporn M B. A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol 2000; 14: 1550–1556, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wright H M, Clish C B, Mikami T, Hauser S, Yanagi K, Hiramatsu R, Serhan C N, Spiegelman B M. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem 2000; 275: 1873–1877, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Juge-Aubry C, Pernin A, Favez T, Burger A G, Wahli W, Meier C A, Desvergne B. DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. Importance of the 5′-flanking region. J Biol Chem 1997; 272: 25252–25259, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol 1996; 12: 335–363, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Xu L, Glass C K, Rosenfeld M G. Coactivator and corepressor complexes in nuclear receptor function. Curr Opin Genet Dev 1999; 9: 140–147, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zhu Y, Qi C, Calandra C, Rao M S, Reddy J K. Cloning and identification of mouse steroid receptor coactivator-1 (mSRC-1), as a coactivator of peroxisome proliferator-activated receptor gamma. Gene Expr 1996; 6: 185–195, [PUBMED], [INFOTRIEVE], [CSA]
- Zhu Y, Qi C, Jain S, Rao M S, Reddy J K. Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J Biol Chem 1997; 272: 25500–25506, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Allred C D, Kilgore M W. Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. Mol Cell Endocrinol 2005; 235: 21–29, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Li M, Lee T W, Mok T S, Warner T D, Yim A P, Chen G C. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. J Cell Biochem 2005; 96: 760–774, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rochette-Egly C. Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell Signal 2003; 15: 355–366, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hu E, Kim J B, Sarraf P, Spiegelman B M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 1996; 274: 2100–2103, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Camp H S, Tafuri S R, Leff T. c-Jun N-terminal kinase phosphorylates peroxisome proliferator-activated receptor-gamma1 and negatively regulates its transcriptional activity. Endocrinology 1999; 140: 392–397, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gardner O S, Dewar B J, Earp H S, Samet J M, Graves L M. Dependence of peroxisome proliferator-activated receptor ligand-induced mitogen-activated protein kinase signaling on epidermal growth factor receptor transactivation. J Biol Chem 2003; 278: 46261–46269, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chana R S, Lewington A J, Brunskill N J. Differential effects of peroxisome proliferator activated receptor-gamma (PPAR gamma) ligands in proximal tubular cells: thiazolidinediones are partial PPAR gamma agonists. Kidney Int 2004; 65: 2081–2090, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zhang B, Berger J, Zhou G, Elbrecht A, Biswas S, White-Carrington S, Szalkowski D, Moller D E. Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma. J Biol Chem 1996; 271: 31771–31774, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Al-Rasheed N M, Chana R S, Baines R J, Willars G B, Brunskill N J. Ligand-independent activation of peroxisome proliferator-activated receptor-gamma by insulin and C-peptide in kidney proximal tubular cells: dependent on phosphatidylinositol 3-kinase activity. J Biol Chem 2004; 279: 49747–49754, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Camp H S, Tafuri S R. Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J Biol Chem 1997; 272: 10811–10816, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Adams M, Reginato M J, Shao D, Lazar M A, Chatterjee V K. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 1997; 272: 5128–5132, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Han J, Hajjar D P, Tauras J M, Feng J, Gotto A M, Jr, Nicholson A C. Transforming growth factor-beta1 (TGF-beta1) and TGF-beta2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma. J Biol Chem 2000; 275: 1241–1246, [PUBMED], [INFOTRIEVE], [CSA]
- Inoue K, Kawahito Y, Tsubouchi Y, Yamada R, Kohno M, Hosokawa Y, Katoh D, Bishop-Bailey D, Hla T, Sano H. Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in human lung cancer. Anticancer Res 2001; 21: 2471–2476, [PUBMED], [INFOTRIEVE], [CSA]
- Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, Inoue K, Hla T, Kondo M. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 2000; 270: 400–405, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bren-Mattison Y, Van Putten V, Chan D, Winn R, Geraci M W, Nemenoff R A. Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 2005; 24: 1412–1422, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wick M, Hurteau G, Dessev C, Chan D, Geraci M W, Winn R A, Heasley L E, Nemenoff R A. Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. Mol Pharmacol 2002; 62: 1207–1214, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Han S, Roman J. Suppression of prostaglandin E2 receptor subtype EP2 by PPARgamma ligands inhibits human lung carcinoma cell growth. Biochem Biophys Res Commun 2004; 314: 1093–1099, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pierce G B, Speers W C. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 1988; 48: 1996–2004, [PUBMED], [INFOTRIEVE], [CSA]
- Jarrard J A, Linnoila R I, Lee H, Steinberg S M, Witschi H, Szabo E. MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis. Cancer Res 1998; 58: 5582–5589, [PUBMED], [INFOTRIEVE], [CSA]
- Kwiatkowski D J. Predominant induction of gelsolin and actin-binding protein during myeloid differentiation. J Biol Chem 1988; 263: 13857–13862, [PUBMED], [INFOTRIEVE], [CSA]
- Dosaka-Akita H, Hommura F, Fujita H, Kinoshita I, Nishi M, Morikawa T, Katoh H, Kawakami Y, Kuzumaki N. Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res 1998; 58: 322–327, [PUBMED], [INFOTRIEVE], [CSA]
- Cultraro C M, Bino T, Segal S. Function of the c-Myc antagonist Mad1 during a molecular switch from proliferation to differentiation. Mol Cell Biol 1997; 17: 2353–2359, [PUBMED], [INFOTRIEVE], [CSA]
- Zhang W, Grasso L, McClain C D, Gambel A M, Cha Y, Travali S, Deisseroth A B, Mercer W E. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 1995; 55: 668–674, [PUBMED], [INFOTRIEVE], [CSA]
- Parker S B, Eichele G, Zhang P, Rawls A, Sands A T, Bradley A, Olson E N, Harper J W, Elledge S J. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 1995; 267: 1024–1027, [PUBMED], [INFOTRIEVE], [CSA]
- Chang T H, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 2000; 60: 1129–1138, [PUBMED], [INFOTRIEVE], [CSA]
- Brown P D, Bloxidge R E, Stuart N S, Gatter K C, Carmichael J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 1993; 85: 574–578, [PUBMED], [INFOTRIEVE], [CSA]
- White E S, Strom S R, Wys N L, Arenberg D A. Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity. J Immunol 2001; 166: 7549–7555, [PUBMED], [INFOTRIEVE], [CSA]
- Strieter R M, Polverini P J, Kunkel S L, Arenberg D A, Burdick M D, Kasper J, Dzuiba J, Van Damme J, Walz A, Marriott D, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995; 270: 27348–27357, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Keshamouni V G, Arenberg D A, Reddy R C, Newstead M J, Anthwal S, Standiford T J. PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia 2005; 7: 294–301, [PUBMED], [INFOTRIEVE], [CSA]
- Adachi M, Taki T, Higashiyama M, Kohno N, Inufusa H, Miyake M. Significance of integrin alpha5 gene expression as a prognostic factor in node-negative non-small cell lung cancer. Clin Cancer Res 2000; 6: 96–101, [PUBMED], [INFOTRIEVE], [CSA]
- Han S, Rivera H N, Roman J. Peroxisome proliferator-activated receptor-gamma ligands inhibit alpha5 integrin gene transcription in non-small cell lung carcinoma cells. Am J Respir Cell Mol Biol 2005; 32: 350–359, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Richards J A, Brueggemeier R W. Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. J Clin Endocrinol Metab 2003; 88: 2810–2816, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yano T, Zissel G, Muller-Qernheim J, Jae Shin S, Satoh H, Ichikawa T. Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. FEBS Lett 2002; 518: 154–158, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dohadwala M, Batra R K, Luo J, Lin Y, Krysan K, Pold M, Sharma S, Dubinett S M. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 2002; 277: 50828–50833, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Green D R, Reed J C. Mitochondria and apoptosis. Science 1998l; 281: 1309–1312, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gross A, McDonnell J M, Korsmeyer S J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899–1911, [PUBMED], [INFOTRIEVE], [CSA]
- Li P, Nijhawan D, Budihardjo I, Srinivasula S M, Ahmad M, Alnemri E S, Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479–489, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nicholson D W, Ali A, Thornberry N A, Vaillancourt J P, Ding C K, Gallant M, Gareau Y, Griffin P R, Labelle M, Lazebnik Y A, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995; 376: 37–43, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Han S, Sidell N, Fisher P B, Roman J. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin Cancer Res 2004; 10: 1911–1919, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Liu Y, Lee M O, Wang H G, Li Y, Hashimoto Y, Klaus M, Reed J C, Zhang X. Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol Cell Biol 1996; 16: 1138–1149, [PUBMED], [INFOTRIEVE], [CSA]
- Lotan R, Xu X C, Lippman S M, Ro J Y, Lee J S, Lee J J, Hong W K. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995; 332: 1405–1410, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996; 10: 940–954, [PUBMED], [INFOTRIEVE], [CSA]
- James S Y, Lin F, Kolluri S K, Dawson M I, Zhang X K. Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells. Cancer Res 2003; 63: 3531–3538, [PUBMED], [INFOTRIEVE], [CSA]
- Shankaranarayanan P, Nigam S. IL-4 induces apoptosis in A549 lung adenocarcinoma cells: evidence for the pivotal role of 15-hydroxyeicosatetraenoic acid binding to activated peroxisome proliferator-activated receptor gamma transcription factor. J Immunol 2003; 170: 887–894, [PUBMED], [INFOTRIEVE], [CSA]
- Xia Z, Dickens M, Raingeaud J, Davis R J, Greenberg M E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270: 1326–1331, [PUBMED], [INFOTRIEVE], [CSA]
- Nguyen T T, Tran E, Nguyen T H, Do P T, Huynh T H, Huynh H. The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis 2004; 25: 647–659, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Schweyer S, Soruri A, Meschter O, Heintze A, Zschunke F, Miosge N, Thelen P, Schlott T, Radzun H J, Fayyazi A. Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation. Br J Cancer 2004; 91: 589–598, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yuan Z, Taatjes D J, Mossman B T, Heintz N H. The duration of nuclear extracellular signal-regulated kinase 1 and 2 signaling during cell cycle reentry distinguishes proliferation from apoptosis in response to asbestos. Cancer Res 2004; 64: 6530–6536, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pettersson F, Couture M C, Hanna N, Miller W H. Enhanced retinoid-induced apoptosis of MDA-MB-231 breast cancer cells by PKC inhibitors involves activation of ERK. Oncogene 2004; 23: 7053–7066, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chen C H, Wang W J, Kuo J C, Tsai H C, Lin J R, Chang Z F, Chen R H. Bidirectional signals transduced by DAPK-ERK interaction promote the apoptotic effect of DAPK. EMBO J 2005; 24: 294–304, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lee W C, Choi C H, Cha S H, Oh H L, Kim Y K. Role of ERK in hydrogen peroxide-induced cell death of human glioma cells. Neurochem Res 2005; 30: 263–270, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tamura Y, Simizu S, Osada H. The phosphorylation status and anti-apoptotic activity of Bcl-2 are regulated by ERK and protein phosphatase 2A on the mitochondria. FEBS Lett 2004; 569: 249–255, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Roovers K, Assoian R K. Integrating the MAP kinase signal into the G1 phase cell cycle machinery. Bioessays 2000; 22: 818–826, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Brandlin I, Hubner S, Eiseler T, Martinez-Moya M, Horschinek A, Hausser A, Link G, Rupp S, Storz P, Pfizenmaier K, Johannes F J. Protein kinase C (PKC)eta-mediated PKC mu activation modulates ERK and JNK signal pathways. J Biol Chem 2002; 277: 6490–6496, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Avis I, Martinez A, Tauler J, Zudaire E, Mayburd A, Abu-Ghazaleh R, Ondrey F, Mulshine J L. Inhibitors of the arachidonic acid pathway and peroxisome proliferator-activated receptor ligands have superadditive effects on lung cancer growth inhibition. Cancer Res 2005; 65: 4181–4190, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Andela V B, Altuwaijri S, Wood J, Rosier R N. Inhibition of beta-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARgamma agonists. FEBS Lett 2005; 579: 1765–1769, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans R M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001; 7: 48–52, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Okano H, Shiraki K, Inoue H, Yamanaka Y, Kawakita T, Saitou Y, Yamaguchi Y, Enokimura N, Yamamoto N, Sugimoto K, Murata K, Nakano T. 15-deoxy-delta-12-14-PGJ2 regulates apoptosis induction and nuclear factor-kappaB activation via a peroxisome proliferator-activated receptor-gamma-independent mechanism in hepatocellular carcinoma. Lab Invest 2003; 83: 1529–1539, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vaidya S, Somers E P, Wright S D, Detmers P A, Bansal V S. 15-Deoxy-Delta12,14-prostaglandin J2 inhibits the beta2 integrin-dependent oxidative burst: involvement of a mechanism distinct from peroxisome proliferator-activated receptor gamma ligation. J Immunol 1999; 163: 6187–6192, [PUBMED], [INFOTRIEVE], [CSA]
- Krzystyniak K L. Current strategies for anticancer chemoprevention and chemoprotection. Acta Pol Pharm 2002; 59: 473–478, [PUBMED], [INFOTRIEVE], [CSA]